CONNECT WITH US Linkedin Twitter #DSEC
Drug Safety Executive Council
Safer Medicines. Faster.
  • |

Upcoming Events

Event Details:

Webinar: Making Sense of the CiPA Initiative: a Paradigm Shift in Cardiac Safety

An exclusive FREE webinar hosted by    /uploadedImages/DSEC_logo_3D_small.jpg 

This webinar has already taken place. However, you can watch a recording of it below.

Originally aired on April 24, 2014.



An informational webinar, discussing the CiPA initiative and improved strategies with the MICE approach. The CEO of ChanTest, Arthur "Buzz" Brown, and one of the authors of the recent CiPA paper, Philip Sager, will be presenting their findings in this field.

CV Safety Assessments During Drug Development- the Need for a New Paradigm 

The current approach, outlined in ICH S7B and E14, to cardiac arrhythmia risk is focused on preclinical and clinical assessments: 1) the effect of new chemical entities on the hERG encoded IKr current and QTc prolongation in animals and 2) measuring QTc prolongation at supratherapeutic exposures in humans, typically during Phase 2 of development. While this approach has largely eliminated the unanticipated presence of new torsadogenic drugs entering the market, it has become clear that there are important limitations to this methodology. Block of hERG alone is often insufficient in predicting delayed repolarization and hERG-related prolongation of repolarization does not necessarily translate into human torsade de pointes risk. Increases in the QTc interval are highly sensitive but not very specific for the prediction of ventricular proarrhythmia risk. The use of the hERG repolarizing ionic current assay (in early nonclinical development) and QTc interval prolongation (in later nonclinical and clinical development) as gatekeepers for the continued development of a new chemical entity has likely led to the inappropriate discontinuation of development programs for drugs with potentially high public health benefits. The talk will focus on these key issues and a potential new approach to drug-induced arrhythmia development. 

Making sense of the CiPA initiative: a paradigm shift in cardiac safety   

This presentation also discusses the present nonclinical (S7B) and clinical (E14) assays for cardiac risk assessment of non-cardiac drugs and how regulators arrived at them. The initial concern was with Torsade de Pointes, a potentially lethal ventricular arrhythmia. TdP occurred infrequently but it was always associated with delayed repolarization and QTc prolongation. The rarity of TdP shifted emphasis to the detection of delayed repolarization. The shortcomings of this approach have become obvious and the CiPA initiative is meant to re-direct emphasis towards predicting the likelihood of TdP.  


      Philip Sager 

Philip Sager, MD, FACC, FAHA, FHRS 
Chair, Scientific Programs Committee      

Buzz Brown      

Arthur M. "Buzz" Brown, MD, PhD 
Founder, President, CEO

       Ernie Bush   Moderator:
Ernie Bush, PhD

Scientific Director
Cambridge Healthtech Associates


Archived Events


An exclusive FREE webinar hosted by
Cambridge Healthtech Associates.

Date: May 22, 2014
Time: 11:00AM (EST)
Click Here to Register! 


An exclusive FREE webinar hosted by Cambridge Healthtech Associates.      

DATE: April 24, 2014
TIME: 11:00AM (PST);
2:00PM (EST)

Click here to register!



An exclusive FREE webinar hosted by Cambridge Healthtech Associates™. 

DATE: March 18, 2014
TIME: 2:00PM (EST)
Register Now! 


Molecular Med Tri-Con 2014 San Francisco, CA 2/9/2014 12:00:00 AM

The 21st International Molecular Medicine Tri-Conference is the industry’s Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology. Spanning six days this year, the Tri-Conference includes an expanded program that includes 6 symposia, 20 short courses, and 15 conference programs. For the first time in over 10 years we’re bringing back a dedicated conference on sequencing. As many will recall this event’s infancy was heavily devoted to the Human Genome Project and we are excited to reintroduce sequencing to this event.

Quick Poll

How many new technology evaluations did your organization conduct in 2011?

CHA Home|Privacy Policy|Terms of Use|Request Information